Trimeris cuts jobs, focuses on revenue

San Francisco-based Trimeris is being applauded by investors for reorganizing the company and initiating a round of layoffs to cut expenses while focusing on revenue. Trimeris developed the HIV therapy Fuzeon with Roche and says it will concentrate on maximizing revenue on the therapy. Meanwhile, its CEO--Steven Skolsky (photo)--is among the first casualties in the cutbacks. Chief scientific officer Dani Bolognesi will add the CEO title to her list of jobs. Trimeris says it will have $65 million on hand by the end of 2007. Its stock jumped 15.5 percent in after-market trading. Trimeris also has other therapies for viral diseases in the pipeline.

- see the press release on the cutbacks
- here's the report on Trimeris from MarketWatch

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.